Children with systemic lupus erythematosus (SLE) have a high prevalence of antiphospholipid (aPL) antibodies and are at increased risk for aPL-related thrombosis. We investigated the association between annexin A5 anticoagulant activity and antibodies to the domain I portion of β2-glycoprotein I (anti-DI antibodies), and propose a potential mechanism for the pathogenesis of aPL-related thrombosis. Using samples from 183 children with SLE collected during the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) trial, we examined resistance to the anticoagulant effects of annexin A5, using the annexin A5 resistance (A5R) assay, and evaluated for anti-DI IgG antibodies. Children with SLE had higher frequency of anti-D1 antibodies (p = 0.014) and significantly reduced A5R compared to pediatric controls: mean A5R = 172 ± 30% versus 242 ± 32% (p < 0.0001). Children with SLE and positive anti-DI antibodies had significantly lower mean A5R levels compared to those with negative anti-DI antibodies: mean A5R = 155 ± 24% versus 177 ± 30% (p < 0.0001). In multivariate analysis, anti-DI antibodies (p = 0.013) and lupus anticoagulant (LA) (p = 0.036) were both independently associated with reduced A5R. Children with SLE have significantly reduced annexin A5 anticoagulant activity that is associated with the presence of LA and anti-DI antibodies.
BerubeCMitchellLSilvermanE. The relationship of antiphospholipid antibodies to thromboembolic events in pediatric patients with systemic lupus erythematosus: A cross-sectional study. Pediatr Res1998; 44: 351–356.
2.
MaleCFoulonDHoogendoornH. Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood2005; 106: 4152–4158.
von SchevenEGliddenDVElderME. Anti-beta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum2002; 47: 414–420.
5.
GattornoMBuoncompagniAMolinariAC. Antiphospholipid antibodies in paediatric systemic lupus erythematosus, juvenile chronic arthritis and overlap syndromes: SLE patients with both lupus anticoagulant and high-titre anticardiolipin antibodies are at risk for clinical manifestations related to the antiphospholipid syndrome. Br J Rheumatol1995; 34: 873–881.
WaheziDMIlowiteNTRajpathakSRandJH. Prevalence of annexin A5 resistance in children and adolescents with rheumatic diseases. J Rheumatol2012; 39: 382–388.
8.
RandJHWuXXQuinnASTaatjesDJ. Resistance to annexin A5 anticoagulant activity: A thrombogenic mechanism for the antiphospholipid syndrome. Lupus2008; 17: 922–930.
9.
RandJHWuXXAndreeHA. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: A “lupus procoagulant” phenomenon. Blood1998; 92: 1652–1660.
10.
RandJHWuXXQuinnAS. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: Evidence from atomic force microscopy and functional assay. Am J Pathol2003; 163: 1193–1200.
11.
RandJHWuXXLapinskiR. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood2004; 104: 2783–2790.
12.
de LaatHBDerksenRHUrbanusRTRoestMde GrootPG. beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood2004; 104: 3598–3602.
13.
DanowskiAKicklerTSPetriM. Anti-beta2-glycoprotein I: Prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol2006; 33: 1775–1779.
14.
GalliMLucianiDBertoliniGBarbuiT. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood2003; 102: 2717–2723.
15.
de LaatBDerksenRHUrbanusRTde GrootPG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood2005; 105: 1540–1545.
16.
de LaatBPengoVPabingerI. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: An international multicenter study. J Thromb Haemost2009; 7: 1767–1773.
17.
de LaatBWuXXvan LummelMDerksenRHde GrootPGRandJH. Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood2007; 109: 1490–1494.
18.
SchanbergLESandborgCBarnhartHX. Premature atherosclerosis in pediatric systemic lupus erythematosus: Risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis Rheum2009; 60: 1496–1507.
19.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
20.
RandJHArslanAAWuXX. Reduction of circulating annexin A5 levels and resistance to annexin A5 anticoagulant activity in women with recurrent spontaneous pregnancy losses. Am J Obstet Gynecol2006; 194: 182–188.
21.
PierangeliSSRandJHLaboratory heterogeneity of antiphospholipid antibodies. In: CerveraRReverterJCKhamashtaM (eds). Handbook of systemic autoimmune diseases, Elsevier B. V, Amsterdam, the Netherlands, 2009.
22.
AgarCvan OsGMMörgelinM. Beta2-glycoprotein I can exist in 2 conformations: Implications for our understanding of the antiphospholipid syndrome. Blood2010; 116: 1336–1343.
23.
RandJH. A snappy new concept for APS. Blood2010; 116: 1193–1194.
24.
de LaatBvan BerkelMUrbanusRT. Immune responses against domain I of beta(2)-glycoprotein I are driven by conformational changes: Domain I of beta(2)-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum2011; 63: 3960–3968.
25.
IversonGMVictoriaEJMarquisDM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci USA1998; 95: 15542–15546.
26.
GalliMLucianiDBertoliniGBarbuiT. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature. Blood2003; 101: 1827–1832.
27.
ErkanDYaziciYPetersonMGSammaritanoLLockshinMD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford)2002; 41: 924–929.
28.
PetriM. Thrombosis and systemic lupus erythematosus: The Hopkins Lupus Cohort perspective. Scand J Rheumatol1996; 25: 191–193.
29.
TektonidouMGLaskariKPanagiotakosDBMoutsopoulosHM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum2009; 61: 29–36.
30.
RandJHWuXXQuinnAS. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: Evidence for a novel effect for an old antimalarial drug. Blood2010; 115: 2292–2299.
